Ironwood announced that Zurampic (lesinurad tablets) is now available for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
Zurampic is a URAT1 inhibitor that was initially approved in December 2015. Xanthine oxidase inhibitors (eg, allopurinol or febuxostat) work by reducing the production of uric acid. Zurampic works by increasing renal excretion of uric acid by selectively inhibiting URAT1 action. The dual mechanism of Zurampic and a xanthine oxidase inhibitor ultimately lower serum uric acid levels by addressing overproduction of uric acid and inefficient excretion.
Zurampic is available as 200mg strength tablets in 5-, 30-, and 90-count bottles.
For more information call (800) 236-9933 or visit Zurampic.com.
This article originally appeared on MPR